Kenneth Grisé, PhD
Ken Joined Sixty Degree Capital in May 2021 as an Investment Analyst. He acts as a science and market expert to help develop Sixty Degree Capital’s biotechnology and healthcare investment portfolio.
Previously, Ken worked on drug discovery for regenerative medicines with biopharma startup Endogena Therapeutics; he worked on developing a diabetes cell therapy with biotech company Sernova; and worked with the Neurobiology Research Group at the Centre for Cellular and Biomolecular Research in Toronto, developing stem cell-based approaches to treat degenerative diseases of the retina and the brain.
Ken is also passionate about scientific outreach and education, and acts as a scientific consultant for the entertainment industry.
Ken holds a Ph.D. in Molecular Genetics from the University of Toronto, as well as an M.Sc. in Kinesiology and B.Sc. in Physiology & Psychology from the University of Western Ontario.